Dyne Therapeutics Inc’s filing revealed that its CEO & President Cox John acquired Company’s shares for reported $0.91 million on Jul 14 ’25. In the deal valued at $9.11 per share,100,000 shares were bought. As a result of this transaction, Cox John now holds 242,179 shares worth roughly $2.7 million.
Then, Scalzo Richard William bought 1,330 shares, generating $19,619 in total proceeds.
Before that, Beskrovnaya Oxana bought 2,132 shares. Dyne Therapeutics Inc shares valued at $31,449 were divested by the Officer at a price of $14.75 per share.
Bernstein initiated its Dyne Therapeutics Inc [DYN] rating to a Mkt perform in a research note published on June 24, 2025; the price target was $13. Evercore ISI started covering the stock on May 29, 2025. It rated DYN as “an Outperform”.
Price Performance Review of DYN
On Friday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -0.27% to $11.16. Over the last five days, the stock has gained 11.04%. Dyne Therapeutics Inc shares have fallen nearly -74.27% since the year began. Nevertheless, the stocks have fallen -52.63% over the past one year.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-07-15, dropping by -4.89 million shares to a total of 15.73 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 20.62 million shares. There was a decline of -31.1%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 12, 2025 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
